MedDataX Logo

Dose Escalation Safety Study of MM-10-001 in Healthy Subjects

NCT00677027 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.

Conditions

  • Healthy

Interventions

OTHER

lentinan

Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.

OTHER

placebo

Placebo

Sponsors & Collaborators

  • Centre for clinical studies, Bergen, Norway

    collaborator UNKNOWN

  • GlycaNova Norge AS

    lead INDUSTRY

Principal Investigators

  • Snorre Ofjord, MD · Centre for clinical studies, Bergen, Norway

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Norway

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677027 on ClinicalTrials.gov